BLUE: bluebirdbio.com Debt to Equity

This price chart illustrating value trends for bluebird bio, Inc. (BLUE), which develops innovative treatments via genome modification, shows a dependence on insurance payouts and therapy safety, where the metric stands at 0.00. Financial stability is constrained by the high cost of procedures and a lack of liquidity. Meanwhile, the company relies on modern cryogenic warehouses and high-tech bioreactors operating at maximum efficiency.

The total debt-to-equity ratio measures the proportion of borrowed funds relative to equity assets, determining the extent of a business's financial dependence on creditors. By analyzing changes in the business's leverage ratio, an investor can assess the resilience of bluebird bio, Inc. (BLUE) to critical liquidity shortages and massive operating losses, which call into question the company's viability amid gene therapy risks.